5 Key Takeaways
-
1
AlloFlo Uveo offers a new option for glaucoma patients experiencing loss of IOP control after MIGS, avoiding bleb-forming procedures.
-
2
Surgeons report significant pressure drops and improved medication adherence in patients treated with AlloFlo Uveo, enhancing recovery.
-
3
The procedure is quick and intuitive, utilizing scleral spacers to create a cyclodialysis cleft, making it accessible for anterior segment surgeons.
-
4
AlloFlo Uveo targets the uveoscleral outflow system, providing an intermediate option before resorting to more invasive conjunctival procedures.
-
5
The technology allows for proactive identification of candidates, enabling earlier intervention to maintain natural outflow and delay filtering surgery.
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.